Radar · Life Sciences in Munich
Best Life Sciences Companies in Munich, Germany
The 115 best Life Sciences companies in Munich, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ITM.
By Rohit KhannaTrends & Stories
115companies tracked
$2.4Bdisclosed funding
1unicorns
56have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × MUNICH
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
51%cloud-native stacks
2024funding peak (by rounds)
2016median founding year
40median Fliar Index™
377kcombined LinkedIn audience
56%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Munich
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ITM Developer of radiopharmaceuticals and radioisotopes for cancer treatment 27Funding top 25%Growth top 35%Moat top 42%Global top 48% All 9 signals ▾Fundingtop 25% Growthtop 35% Moattop 42% Globaltop 48% Talenttop 50% Marketbottom 38% Techbottom 26% Newsbottom 20% Fin. healthbottom 10% Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $681M | 12 mo ago | 54 | Oliver Buck Founder | TYPO3 CMSPHPBootstrap+8 | Top 5M | — | 1 award |
| 2 | ATAI 🦄 Biopharmaceutical company accelerating the development of mental health treatments | $387M | 63 mo ago | 119 | Lars Christian Wilde Co-Founder | — | — | — | — |
| 3 | CatalYm Developer of drugs for the treatment of cancer 37Funding top 24%Moat top 28%Patents top 42%Innovation top 45% All 9 signals ▾Fundingtop 24% Moattop 28% Patentstop 42% Innovationtop 45% Growthtop 48% Globalbottom 39% Marketbottom 33% Techbottom 33% Newsbottom 17% Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $261M | 23 mo ago | 18 | — | WordPressApple iCloud MailMicrosoft 365+20 | Top 10M | 23 patents Therapeutic anti‑GDF15 antibodies for neoadjuvant and combination cancer treatment | — |
| 4 | Tubulis Technologies Developer of antibody-drug conjugates for the treatment of cancer 60News top 15%Funding top 18%Growth top 20%Patents top 27% All 10 signals ▾Newstop 15% Fundingtop 18% Growthtop 20% Patentstop 27% Moattop 28% Innovationtop 35% Talenttop 50% Marketbottom 42% Globalbottom 42% Techbottom 32% News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $214M | 8 mo ago | 33 | Dominik Schumacher Co-Founder & CEO | WordPressMySQLPHP+14 | Top 5M | 70 patents Phosphorus‑based linkers for antibody‑drug conjugates targeting cancer antigens | — |
| 5 | Isarna Therapeutics Developer of TGF-B inhibitors based therapies for ophthalmic, fibrotic diseases and cancer | $158M | 145 mo ago | 3 | — | — | — | 64 patents Antisense oligonucleotide therapeutics targeting TGF‑β pathways for ocular disease treatment | — |
| 6 | iOmx Developer of checkpoint modulators for treating cancer | $120M | 56 mo ago | 33 33 → 53 (+61%) | — | WordPressMySQLPHP+10 | Top 50M | — | — |
| 7 | Morphochem German, late clinical stage biopharma developing oxazolidinone antibiotics for clostridium difficile… | $68M | 299 mo ago | 1 | Alexis Rideau CEO | — | — | 28 patents Hybrid oxazolidinone‑quinolone antibiotics for parenteral bacterial infection treatment | — |
| 8 | Sapiens Neuro Developer of brain stimulation device to treat neurodegenerative disorders | $56M | 150 mo ago | 59 | Sjaak Deckers ex-CEO | — | — | — | — |
| 9 | AdjuCor Developer of biventricular assistance device for chronic heart failure | $48M | 48 mo ago | 40 40 → 25 (-38%) | — | WordPressApple iCloud MailMicrosoft 365+20 | Top 50M | 49 patents Implantable cardiac ventricular assist devices with expandable pumps and structured surfaces | — |
| 10 | HMNC Brain Health Developer of targeted therapies for depression and other neuropsychiatric disorders | $41M | 44 mo ago | 18 | — | Apple iCloud MailMicrosoft 365PHP+5 | Top 50M | — | — |
| 11 | Curacyte Hemoximer to resolve the hypotension associated with distributive shock | $38M | 255 mo ago | 51 | Helmut Giersiefen CEO | — | — | 13 patents Developing peptide‑based inhibitors for urokinase, factor Xa, and transglutaminase enzymes | — |
| 12 | Definiens Provides image analysis and data mining solutions for quantitative digital pathology in the healthcare… | $33M | 137 mo ago | 136 | — | — | — | 137 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | inveox Manufacturing automated laboratory solutions for biopsy sample preparation | $26M | 82 mo ago | 36 | Maria Driesel Co-Founder & CEO | — | — | 16 patents Automated histology sample preparation and 3D pathology imaging systems | — |
| 14 | Innovative Molecules Developer of drugs to treat Herpes simplex-induced diseases | $24M | 60 mo ago | — | Gerald Kleymann Founder & CEO | MODXPHPUNIX+7 | Top 50M | 102 patents Antiviral small‑molecule thiazole/helicase‑primase inhibitors, including deuterated, enantiomeric, solid forms. | — |
| 15 | iThera Medical Solutions in photonic molecular imaging | $24M | 42 mo ago | 31 | — | — | — | 38 patents Patents concentrated in health & consumer products | — |
| 16 | ADVITOS Provider of multi-organ support systems | $24M | 60 mo ago | 88 88 → 89 (+1%) | Claus Jessen CEO | WordPressMySQLSalesforce+21 | Top 10M | 34 patents Extracorporeal CO₂ removal and lung support dialysis systems for medical respiratory therapy | 1 partnership |
| 17 | Leon-nanodrugs Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics 32Product top 21%Patents top 24%Innovation top 26%Moat top 32% All 10 signals ▾Producttop 21% Patentstop 24% Innovationtop 26% Moattop 32% Fundingtop 39% Talentbottom 49% Globalbottom 40% Techbottom 39% Newsbottom 21% Marketbottom 20% Product: 9 distinct product lines · Company stage: Series D Patents: 93 patents matched (strict assignee match) · 73 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $20M | 22 mo ago | 8 | Comelia Beier Co-Founder | WordPressMySQLPHP+18 | Top 50M | 93 patents Microfluidic aseptic mixing and disposable reactors for lipid nanoparticle drug production | — |
| 18 | PreOmics Provider of reagents and instruments for proteomics research | $19M | 53 mo ago | 22 | Nils Kulak Co-Founder & CEO | Webflow EcommerceWebflowSalesforce+17 | Top 10M | 59 patents Proteomics sample preparation and magnetic protein fractionation for mass spectrometry analysis | 1 job opening |
| 19 | NeuroCare Group Provider of noninvasive neurotechnology and personalized mental healthcare platform 48Tech top 29%Growth top 37%Moat top 39%Funding top 40% All 10 signals ▾Techtop 29% Growthtop 37% Moattop 39% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 39% Marketbottom 34% Newsbottom 18% Tech: 48 technologies across 5/8 capability areas · Cloud: Cloudflare Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $17M | 16 mo ago | 14 | Thomas Mechtersheimer Founder & CEO | Cart FunctionalityWooCommerceWordPress+28 | Top 5M | 9 patents Adaptive transcranial stimulation systems integrating real-time physiological feedback for personalized therapy | 1 partnership |
| 20 | mbiomics Provider of a genomic-based platform for microbiome-based therapeutics development 21Funding top 39%Patents top 39%Moat top 42%Innovation top 50% All 6 signals ▾Fundingtop 39% Patentstop 39% Moattop 42% Innovationtop 50% Globalbottom 36% Marketbottom 26% Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 1 mo ago | 7 | — | — | — | 13 patents RNA purification methods and microbiome analysis/composition technologies for diagnostic applications | — |
| 21 | Micromet Antibody-based therapies for the treatment of cancer | $10M | 212 mo ago | 15 | — | — | — | 354 patents Bispecific single-chain antibody engineering for targeted immunotherapy, especially CD19×CD3 therapeutics. | — |
| 22 | XO Life Provider of digital platform for pharmaceutical and medical device treatment support 48Patents top 19%Moat top 25%Talent top 28%Growth top 35% All 11 signals ▾Patentstop 19% Moattop 25% Talenttop 28% Growthtop 35% Fundingtop 40% Innovationtop 44% Productbottom 45% Techbottom 44% Globalbottom 44% Marketbottom 28% Newsbottom 22% Patents: 82 patents matched (strict assignee match) · 29 filings since 2022 vs 28 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 82 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $10M | 21 mo ago | 25 | Philipp Naegelein Co-Founder | WebflowAmazon Web ServicesMicrosoft Clarity+9 | Top 50M | 82 patents Molecular biology automation: nucleic acid synthesis, fluorescence imaging, and spectral/auto‑focus instrumentation. | — |
| 23 | ImevaX Vaccines for chronic and nosocomical infections | $10M | 135 mo ago | 1 | — | — | — | 20 patents Therapeutic treatments targeting Helicobacter pylori infections | — |
| 24 | Hepa Wash Extracorporeal Kidney and Liver dialysis therapy | $7M | — | 88 | Bernhard Kreymann Founder | — | — | 63 patents Extracorporeal respiratory support and advanced dialysis technologies | — |
| 25 | Brainlab Software and integrated solutions for surgical and radiotherapy applications 82Fin. health top 18%Patents top 19%Innovation top 27%Tech top 28% All 12 signals ▾Fin. healthtop 18% Patentstop 19% Innovationtop 27% Techtop 28% Markettop 29% Moattop 29% Partnerstop 41% Fundingtop 43% Globaltop 45% Producttop 46% Growthtop 50% Newsbottom 23% Fin. health: Revenue ~$459M · Revenue +18% YoY Patents: 2,839 patents matched (strict assignee match) · 676 filings since 2022 vs 939 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $7M | 18 mo ago | 348 | — | SentryApple iCloud MailNode.js+18 | Top 1M | 2,839 patents Image-guided neurosurgery, radiation therapy planning, and AI-driven medical imaging analysis | 3 launchs |
| 26 | Libify A mobile emergency call system | $7M | 92 mo ago | 55 | — | HubSpot CMS HubEnvoyBootstrap+18 | Top 1M | — | — |
| 27 | Climedo Provider of digital database platform for clinical research | $6M | 52 mo ago | 62 | Sascha Ritz Co-Founder & CEO | TypeScriptQuillBootstrap+13 | Top 50M | — | — |
| 28 | Reactive Robotics Developer of robotic hospital equipment for early mobilization | $6M | 21 mo ago | 18 | — | — | — | 107 patents Patient rehabilitation hardware: modular coupling and support devices for limb and body positioning. | — |
| 29 | Ovo Labs Developer of therapeutics designed to improve the quality of human eggs 37Talent top 28%Growth top 45%Funding top 48%Global bottom 45% All 6 signals ▾Talenttop 28% Growthtop 45% Fundingtop 48% Globalbottom 45% Techbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 13 mo ago | — | Oleksandr Yagensky Co-Founder & Co-CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | Top 10M | — | 2 awards |
| 30 | Kumovis Developer of 3D-printing systems | $5M | 72 mo ago | 20 | Sebastian Pammer Co-Founder | — | — | 52 patents 3D‑printed orthopedic implants and additive manufacturing hardware for medical device production | — |
| 31 | Sedivention Developer of a minimally invasive cryo-ablation therapy for obesity. 22Talent top 38%Funding top 43%Moat top 45%Market bottom 37% All 7 signals ▾Talenttop 38% Fundingtop 43% Moattop 45% Marketbottom 37% Patentsbottom 33% Globalbottom 33% Innovationbottom 29% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $4M | 1 mo ago | — | André Burch Co-Founder | — | — | 2 patents Cryogenic ablation tools for minimally invasive tumor destruction | — |
| 32 | Virtonomy Provider of virtual patient simulation for medical device development | $4M | 38 mo ago | 18 | Simon Sonntag Co-Founder & CEO | WordPress Block EditorWordPressMySQL+23 | Top 50M | 10 patents Automated virtual patient fitting and visual analysis for medical device design and testing. | — |
| 33 | IRUBIS Developer of analytical technology for real-time bioprocess monitoring and analysis | $3M | 21 mo ago | 15 15 → 20 (+33%) | Lorenz Mirle Co-Founder | — | — | 8 patents Optical spectroscopy flow cells and disposable bioreactors for bioprocess monitoring | — |
| 34 | SurgicEye Developer of imaging technologies to assist in image-guided surgery | $3M | 163 mo ago | 7 | Joerg Traub CEO | — | — | 61 patents Image-guided brachytherapy planning and real-time radiotherapy dose calculation systems | — |
| 35 | Cellbyte AI-driven analytics platform that enables pricing and market access professionals in the pharmaceutical… 40Talent top 28%AI top 35%Funding top 39%Global bottom 48% All 6 signals ▾Talenttop 28% AItop 35% Fundingtop 39% Globalbottom 48% Techbottom 43% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-driven, natural language processing rank vs industry peers · Fliar Intelligence Index 40/100 | $3M | 7 mo ago | — | Felix Steinbrenner Co-Founder | Framer SitesApple iCloud MailGoogle Workspace+9 | Top 50M | — | — |
| 36 | UniteLabs Provider of an automation operating system for laboratory workflows 37Talent top 38%AI top 45%Funding bottom 43%Market bottom 37% All 5 signals ▾Talenttop 38% AItop 45% Fundingbottom 43% Marketbottom 37% Globalbottom 37% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-driven rank vs industry peers · Fliar Intelligence Index 37/100 | $3M | 14 mo ago | — | Robert Zechlin Co-Founder & Co-CEO | — | — | — | — |
| 37 | Thermosome Developer of targeted tumor therapy combined with immune stimulation for cancer | $2M | 122 mo ago | 17 | Martin Hossann Principal Scientist & Co-Founder | — | — | 42 patents Specialized oligoglycerol-based lipids for drug delivery nanoparticles | — |
| 38 | smartbax Developer of multi-targeted antibacterial compounds 14Talent top 38%News top 43%Moat top 48%Funding top 49% All 6 signals ▾Talenttop 38% Newstop 43% Moattop 48% Fundingtop 49% Globalbottom 32% Marketbottom 22% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated News: 2 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 8 mo ago | 3 | Stephan Sieber Co-Founder | — | — | — | — |
| 39 | SYNLAB Provider of medical diagnosis and clinical laboratory analysis services | $2M | 113 mo ago | 28,693 | Mathieu Floreani CEO | TYPO3 CMSApple iCloud MailMicrosoft 365+11 | Top 1M | 5 patents Renal disease prognostic biomarkers using homoarginine for clinical diagnostic prediction. | — |
| 40 | SAW Instrument Instruments for analyzing biomolecular interactions. | $1M | 183 mo ago | 11 | Stefan Duhr CEO | — | — | — | — |
| 41 | Nanion Technologies Develops Automated patch clamp system | $1M | 76 mo ago | 78 | — | WordPressMySQLPHP+40 | Top 10M | 3 patents Ion‑channel electrophysiology platforms and microfluidic pressure‑control valve technology. | — |
| 42 | Arivis Biomedical big image data and compliance software | $998K | 125 mo ago | 34 34 → 25 (-26%) | — | — | — | 13 patents Advanced 3D medical image visualization and segmentation alignment for AR/VR platforms | — |
| 43 | Intana Bioscience Provider of services in assay development and screening on FCCS | $908K | 81 mo ago | 8 | Frank Becker Co-Founder & MD | — | — | 10 patents High‑complexity siRNA library production and FCCS‑based biomolecular interaction analysis. | — |
| 44 | NanoTemper Develops tools for protein characterization & analysis | $830K | 76 mo ago | 240 | Philipp Baaske Co-Founder & Co-CEO | WordPressApple iCloud MailMicrosoft 365+27 | Top 5M | 8 patents Thermophoretic and optical analysis of particles in microfluidic capillary systems | 1 launch |
| 45 | BioVariance Crowd-sourced platform for capture and analysis of drug dosage, adherence and adverse events | $260K | 77 mo ago | 18 | Josef Scheiber Founder & MD | Cart FunctionalityShopifyVisa+19 | Top 50M | 2 patents Syringe‑compatible medicament delivery devices and associated usage systems | — |
| 46 | Vermicon Developer of a gene probe technology to diagnose microorganisms | $245K | 116 mo ago | 9 | Jiri Snaidr Founder & CEO | TYPO3 CMSPHPYouTube+8 | Top 10M | 32 patents Rapid, specific detection methods for microorganisms, especially gram‑positive bacteria, in diagnostics. | — |
Top 12 Life Sciences companies in Munich
#1
Series E · Munich, Bavaria · founded 2004 · 54 employees$681Mraised▾
Series E · Munich, Bavaria · founded 2004 · 54 employees
Developer of radiopharmaceuticals and radioisotopes for cancer treatment. The company's lead product is radionuclide therapy candidate LuCaFab (ITM-31) for the treatment of malignant brain tumors. The company offers medical isotopes like EndolucinBeta and TOCscan. It also offers radiolabelling and quality control equipment like iQS - Theranostics Synthesizer, iQS Ga-68, Fluidic Labeling, Module Reagent Set Manual, and 177Lu Labeling.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 25%Growth
top 35%Moat
top 42%Global
top 48%Talent
top 50%Market
bottom 38%Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) · Last round Conventional Debt (May 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 5/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 6.3% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- May 2025Conventional Debt$262.5M
- Jun 2024Series E$204.4M
- Jun 2023Series E$273M
- Mar 2022Series D$36.4M
Founders & team
Investors
Temasek, BlackRock, Qatar Investment Authority, Carbyne Equity Partners, ATHOS, European Investment Bank
Tech stack
Apache Http ServerBootstrapIonosJqueryLightboxMatomo Analytics
#2
Acquired · Munich, Bavaria · founded 2015 · 33 employees$214.1Mraised▾
Acquired · Munich, Bavaria · founded 2015 · 33 employees
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
News
top 15%Funding
top 18%Growth
top 20%Patents
top 27%Moat
top 28%Innovation
top 35%News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY · 12 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series C (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 4.7% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series C$401M
- Mar 2024Series B$138.8M
- Aug 2022Grant (prize money)—
- May 2022Series B$63.1M
Founders & team
Investors
Nextech Invest, Deep Track Capital, Frazier Life Sciences, Andera Partners, BioMedPartners, Bayern Kapital
Tech stack
All-InklApache Http ServerBorlabs CookieCore-JsElementorJquery
#3
Series A · Munich, Bavaria · founded 2020 · 7 employees$14Mraised▾
Series A · Munich, Bavaria · founded 2020 · 7 employees
Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 39%Patents
top 39%Moat
top 42%Innovation
top 50%Global
bottom 36%Market
bottom 26%Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (Apr 2026)
Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 10k LinkedIn followers — 2.7% of this cohort's audience
Funding rounds
- Apr 2026Series A$14.1M
- Mar 2023Series A$14M
Investors
Bayern Kapital, HTGF, MIG Fonds
#4
Seed · Munich, Bavaria · founded 2021$4.2Mraised▾
Seed · Munich, Bavaria · founded 2021
{}
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Talent
top 38%Funding
top 43%Moat
top 45%Market
bottom 37%Patents
bottom 33%Global
bottom 33%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (May 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 2 patents
Audience (LinkedIn): 449 LinkedIn followers
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Seed$3.4M
- Nov 2024Seed$843.1K
Founders & team
Investors
HTGF, Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Superangles, Cambridge Venture Partners, BioVaria
#5
Series D · Munich, Bavaria · founded 2016 · 18 employees$260.6Mraised▾
Series D · Munich, Bavaria · founded 2016 · 18 employees
Developer of drugs for the treatment of cancer. The lead candidate includes CTL-002 which works by neutralizing tumour-produced proteins called GDF-15. It is used to treat cancer and autoimmune disease.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 24%Moat
top 28%Patents
top 42%Innovation
top 45%Growth
top 48%Global
bottom 39%Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) · Last round Series D (Jul 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents · Soonicorn
Patents: 23 patents matched (strict assignee match) · 23 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jul 2024Series D$150M
- Nov 2022Series C$51.3M
- Nov 2020Series B$59.3M
- 2016Seed—
Investors
BioGeneration Ventures, Canaan, Bioqube Ventures, Forbion, Omega Funds, Gilde Healthcare
Tech stack
Animate.CssAosApple Icloud MailContact Form 7Core-JsFont Awesome
#6
Seed · Munich, Bavaria · founded 2024$3.2Mraised▾
Seed · Munich, Bavaria · founded 2024
AI-driven analytics platform that enables pricing and market access professionals in the pharmaceutical industry. It leverages natural language processing that enables users to extract insights from vast amounts of pharmaceutical data, streamlining the process of launching new drugs.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Talent
top 28%AI
top 35%Funding
top 39%Global
bottom 48%Tech
bottom 43%Market
bottom 25%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Product described with: ai-driven, natural language processing
Funding: Raised $3.2M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Seed (Nov 2025)
Funding rounds
- Nov 2025Seed$2.8M
- Seed$500K
Founders & team
Investors
Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels
Tech stack
Apple Icloud MailCloudflareFramer SitesGoogle AnalyticsGoogle Font ApiGoogle Tag Manager
#7
Seed · Munich, Bavaria · founded 2021 · 3 employees$2.1Mraised▾
Seed · Munich, Bavaria · founded 2021 · 3 employees
Developer of multi-targeted antibacterial compounds. The company creates multi-targeted antibacterial compounds that are effective against multi-drug resistance infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Fliar Intelligence Index™ 14how this company ranks against its industry peers
Talent
top 38%News
top 43%Moat
top 48%Funding
top 49%Global
bottom 32%Market
bottom 22%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
News: 2 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 1k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · hiring: Senior Scientist in Structural Biology and Data Science, Laboratory Technician
Funding rounds
- Oct 2025Seed$5.5M
- May 2023Seed$1.3M
- Seed—
Founders & team
Investors
Boehringer Ingelheim Venture Fund, HTGF, Bayern Kapital, UnternehmerTUM, Anobis Asset
#8
Series B · Munich, Bavaria · founded 2015 · 14 employees$17Mraised▾
Series B · Munich, Bavaria · founded 2015 · 14 employees
Provider of noninvasive neurotechnology and personalized mental healthcare platform. The organization develops and supplies digital therapy systems combined with clinical protocols and training for transcranial magnetic stimulation, neurofeedback, EEG, and related neurological assessment tools. It offers a software-based best practice platform that supports clinicians in delivering individualized care through integrated devices, digital workflows, and therapy monitoring. The platform is deployed in its own network of clinics and licensed to third-party practices.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Tech
top 29%Growth
top 37%Moat
top 39%Funding
top 40%Patents
top 44%Talent
bottom 49%Tech: 48 technologies across 5/8 capability areas · Cloud: Cloudflare · Devops: Envoy, Nginx
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 5/10 · IP moat: 9 patents · 4 curated direct competitors tracked
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. bm-t beteiligungsmanagement thüringen GmbH) announced in 12 mo
Funding rounds
- Feb 2025Series B$20M
- Apr 2024Series A$17M
- Sep 2021Seed—
- Grant (prize money)—
Founders & team
Investors
TVM Capital Healthcare, Palo Santo, Apeiron Investment Group, re.Mind Capital, Beteiligungsmanagement Thuringen, Impact Expansion
Tech stack
Anime.JsCart FunctionalityCdnjsCloudflareCloudflare Bot ManagementContact Form 7
#9
Seed · Munich, Bavaria · founded 2025$5.3Mraised▾
Seed · Munich, Bavaria · founded 2025
Developer of therapeutics designed to improve the quality of human eggs. The therapies aim of extending womens reproductive timelines by addressing age-related deterioration in oocyte quality, enhancing fertility and increasing the chances of successful in-vitro fertilization.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 28%Growth
top 45%Funding
top 48%Global
bottom 45%Tech
bottom 42%Market
bottom 31%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $5.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Apr 2025)
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Apr 2025Seed$5.3M
Founders & team
Investors
Creator Fund, LocalGlobe, Blue Wire Capital, Ahren
Tech stack
AngularCart FunctionalityCore-JsGodaddyGoogle Font ApiHsts
#10
Series D · Munich, Bavaria · founded 2011 · 8 employees$20.3Mraised▾
Series D · Munich, Bavaria · founded 2011 · 8 employees
Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics. The company’s systems support process development and GMP production of nanoparticles. They engineer technology that aims to redefine precision and performance in nanoparticle production. The company empowers partners to accelerate the development of next-generation therapeutics.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Product
top 21%Patents
top 24%Innovation
top 26%Moat
top 32%Funding
top 39%Talent
bottom 49%Product: 9 distinct product lines · Company stage: Series D
Patents: 93 patents matched (strict assignee match) · 73 filings since 2022 vs 20 in 2017-21 · Latest publication 2026
Innovation: 93 patents (top 30% of patent-holders) · 73 filings since 2022 vs 20 in 2017-21 · 9 product lines
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Aug 2024Series D—
- Apr 2020Series B—
- Jul 2015Series A$20.3M
Founders & team
Investors
Eckenstein-Geigy-Foundation, CD-Venture, Evotec, BayBG Venture Capital, TVM Capital, Signet Healthcare Partners
Tech stack
WordpressMysqlPhpYoast SeoNginxSite Kit
#11
Series B · Munich, Bavaria · founded 1989 · 348 employees$7.3Mraised▾
Series B · Munich, Bavaria · founded 1989 · 348 employees
Brainlabs develops hardware and software focused on surgery and radiotherapy. Also offers patient data tools for collaboration and image sharing. It creates and integrates products for surgical planning, navigation, data management, intraoperative imaging and surgical follow-up. Radiotherapy offerings help providers plan, monitor and deliver radiation treatment. Has invested in Jan Medical, maker of a brain sensing and diagnostic device.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Fin. health
top 18%Patents
top 19%Innovation
top 27%Tech
top 28%Market
top 29%Moat
top 29%Fin. health: Revenue ~$459M · Revenue +18% YoY · Revenue 62.8x total funding
Patents: 2,839 patents matched (strict assignee match) · 676 filings since 2022 vs 939 in 2017-21 · Latest publication 2026
Innovation: 2,839 patents (top 1% of patent-holders) · 676 filings since 2022 vs 939 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 147k LinkedIn followers — 39.0% of this cohort's audience
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Nov 2024Series B$5.4M
- Jul 2023Series B—
- Jul 2023Conventional Debt$56M
- Sep 2018Series A—
Investors
EMH Partners, European Investment Bank, Intel Capital, Nexstim, W Capital Partners
Tech stack
Animate.CssApple Icloud MailBootstrapCalendlyCloudflareContact Form 7
#12
Seed · Munich, Bavaria · founded 2017$3Mraised▾
Seed · Munich, Bavaria · founded 2017
Provider of an automation operating system for laboratory workflows. It offers a vendor-agnostic integration layer unifying hardware, data, and APIs across the lab. A flexible logic layer allows automation of workflows, from single experiments to full-facility control. The system includes AI-ready infrastructure for real-time control, bridging digital insights and physical execution. It provides low-level control of liquid handlers via a Python SDK, enabling scalable automation. Fleet management capabilities utilize modern DevOps tools for efficient workflow deployment and management. The platform facilitates AI-driven lab operations through self-describing interfaces and workflow generation libraries. A secure, accessible data storage solution centralizes structured and unstructured data. Finally, it offers bidirectional connectivity, an open cloud API, a production-ready workflow engine, and a modular automation toolbox enabling lab-as-code practices.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Talent
top 38%AI
top 45%Funding
bottom 43%Market
bottom 37%Global
bottom 37%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
AI: Product described with: ai-driven
Funding: Raised $3.0M across 2 rounds · 2 rounds over 9 yrs (0.2/yr) · Last round Seed (Apr 2025)
Funding rounds
- Apr 2025Seed$3M
- Nov 2017Seed$10.2K
Founders & team
Investors
Venture Kick, NAP, PUSH, Acurio Ventures, LANA Ventures, Omaangels
Funding & investor landscape
$2.4Btotal disclosed funding
48companies funded
124disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Oliver Buck
Founder · ITM
Steffen Schuster
CEO · ITM
Dominik Schumacher
Co-Founder & CEO · Tubulis Technologies
Jonas Helma-Smets
Co-Founder & CSO · Tubulis Technologies
André Burch
Co-Founder · Sedivention
Ute Nollert
Founder & CEO · Sedivention
Felix Steinbrenner
Co-Founder · Cellbyte
Samuel Moreira
Co-Founder · Cellbyte
Stephan Sieber
Co-Founder · smartbax
Marco Janezic
Co-Founder · smartbax
Thomas Mechtersheimer
Founder & CEO · NeuroCare Group
Oleksandr Yagensky
Co-Founder & Co-CEO · Ovo Labs
Prism market signals · Germany · country-scoped Prism corpus, 141,341 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MUNICH · Health & Bio
How research on Biotechnology in Munich is moving
A read on the academic research around Biotechnology in Munich — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 54 papers.
TU Munich and allied institutes lead Munich's moderately optimistic biotechnology research, focusing on bacterial genetics and RNA gene delivery, with growing recent output and minor environmental concern.
54 papers · stance +0.47 · 46% breakthrough · 20% concern
top institutions
- Technical University of Munich43
- Leibniz-Institute for Food Systems Biology at the Technical University of Munich6
- Center for Integrated Protein Science Munich5
- Munich University of Applied Sciences1
- Munich Leukemia Laboratory1
leading researchers
Mirko Wagner · Angel Angelov · Antoni Lichev · Céline Heinemann · Fabian Dick · Ignazio Piseddu
prism intelligence · tone & topics
91% positive · 2% critical tone
HealthPharmaceuticalsAgricultureBiologyMedical ResearchClinical Trials
▲
Breakthroughs21 · 39%
▲ 33%→35% share
▲1.1× share momentum0 median citations62% since 2021mostly methods-led
Gene therapy research is rising — Gene sub-topic gained 3 papers as Breakthroughs share grew from 33% to 35%.
rising sub-themes (early→recent)
- Gene3
- In vivo2
- Exosome complex2
- TLR72
- RNase P2
Landmark Shifting the limits in wheat research and breeding using a fully annotated reference genome · 3,312 cites
◆
Advancements16 · 30%
▼ 44%→27% share
▼0.6× share momentum0 median citations62% since 2021mostly empirical
Advancements share cooling sharply from 44% to 27%, despite In vivo and Hybrid sub-topics rising.
rising sub-themes (early→recent)
- In vivo2
- Selection (genetic algorithm)1
- Hybrid1
- Population1
- Genomic selection1
Landmark Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia · 726 cites
▼
Concerns9 · 17%
▼ 22%→19% share
▼0.9× share momentum0 median citations78% since 2021mostly reviews
Gene and Manure concerns intensifying simultaneously, each gaining 2 papers within a shrinking 22%-to-19% concern share.
rising sub-themes (early→recent)
- Gene2
- Manure2
- Broiler2
- Root system1
- Domestication1
Landmark Safety assessment of probiotics for human use · 758 cites
Common questions
How many Life Sciences companies are there in Munich, Germany?
Radar tracks 115 indexable Life Sciences companies headquartered in Munich, Germany that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Munich, Germany?
The Life Sciences companies in Munich, Germany on this list have raised a combined $2.4B in disclosed equity funding across 48 funded companies.
Which is the highest-funded Life Sciences company in Munich, Germany?
ITM is the highest-funded Life Sciences company in Munich, Germany, with $681M in disclosed equity funding.
How many Life Sciences companies in Munich, Germany are funded?
48 of the 115 Life Sciences companies in Munich, Germany on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Munich, Germany?
1 Life Sciences company in Munich, Germany on this list is valued at $1B or more.
Who are the top investors in Munich, Germany Life Sciences companies?
The most active investors in Munich, Germany Life Sciences companies on this list include Bayern Kapital, Europa, HTGF, BioVaria, EIT Health.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.